Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate for urticarial vasculitis

P S Stack1

  • 1Dallas Diagnostic Association, TX 75230.

Annals of Allergy
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Urticarial vasculitis can be challenging to treat. Low-dose oral methotrexate effectively treated a corticosteroid-dependent patient, allowing medication withdrawal.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Echocardiography for mitral valve prolapse?

Postgraduate medicine·1999
Same author

Pap smears. Still a reliable screening tool for cervical cancer.

Postgraduate medicine·1997
Same author

Trichinosis. Still a public health threat.

Postgraduate medicine·1995
Same author

Medicine for the masses: what suffers?. Interview by Lisa Schnirring.

Postgraduate medicine·1993
Same author

Ovarian hyperstimulation syndrome.

The American journal of medicine·1991
Same author

Ogilvie's syndrome. Would you recognize it?

Postgraduate medicine·1991

Area of Science:

  • Immunodermatology
  • Rheumatology
  • Pharmacology

Background:

  • Urticarial vasculitis is an inflammatory condition often requiring systemic corticosteroids.
  • Refractory cases pose significant treatment challenges.
  • Alternative therapeutic options are needed for corticosteroid-dependent patients.

Observation:

  • A patient with severe urticarial vasculitis was unresponsive to multiple treatments.
  • Systemic corticosteroids provided partial control but were associated with significant side effects.
  • Low-dose oral methotrexate was trialed as an alternative therapy.

Findings:

  • Complete remission of urticarial vasculitis was achieved with low-dose oral methotrexate.
  • Systemic corticosteroids were successfully withdrawn after initiating methotrexate.

Related Experiment Videos

  • The patient tolerated methotrexate well, indicating an acceptable safety profile.

    • Implications:

    • Low-dose oral methotrexate may be a viable and safe treatment option for selected patients with urticarial vasculitis.
    • This approach could reduce reliance on long-term systemic corticosteroids and their associated adverse effects.
    • Further research into methotrexate's efficacy and safety in urticarial vasculitis is warranted.